Actively Recruiting
Italian Observational Study on CAR-T Therapy for Lymphoma
Led by Paolo Corradini · Updated on 2024-04-01
5300
Participants Needed
1
Research Sites
530 weeks
Total Duration
On this page
Sponsors
P
Paolo Corradini
Lead Sponsor
A
Annalisa Chiappella
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting. Partecipants will be asked to agree to their clinical data collection and to partecipate to the optional biological study that aims to evaluate biomarkers of toxicity and response (clinical characteristics, cytokine profile, cellcomposition and type of the CAR-T cell product, lymphoma genomics). The study will evaluate even the disease response according to lugano criteria by PET and CT in routine clinical activity.
CONDITIONS
Official Title
Italian Observational Study on CAR-T Therapy for Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with diagnosis of DLCBL, PMBCL, MCL and FL eligible for CAR-T treatment with commercially available products in Italy.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione IRCCS Istituto Nazionale Tumori
Milan, Italy, 20133
Actively Recruiting
Research Team
P
Paolo Corradini, Professor
CONTACT
A
Anisa Bermema, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here